Federal Agents Seized Counterfeit Ozempic and Warned the Public. Prosecutors Say the Smuggling Kept Going for Months.

I used to think the worst thing a fake drug could do was nothing. You pay for medicine, you get a sugar pill, you’re out the money and no better off. Passive. Then I read what has actually turned up inside counterfeit Ozempic pens, and the picture flipped: some of these fakes aren’t empty at all. They can do the biological opposite of what the label promises, and federal prosecutors just put two names to the pipeline that allegedly brought them here.

On September 29, the U.S. Attorney’s Office for the Middle District of Florida and the Justice Department’s Criminal Division announced federal charges against Swapnadip Roy, 33, and Vicky Ramancha, 37, both Indian nationals, over a conspiracy to smuggle counterfeit Ozempic into the U.S. drug supply. According to the indictment, they and their co-conspirators sourced fake semaglutide from unauthorized suppliers in China, dressed it up with fraudulent packaging, inserts, pen labels, and needles built to fool pharmacies and patients, then sold it to distributors at heavily discounted prices. The alleged distribution ran from July 2023 into April 2024.

Look hard at that window. In December 2023, right in the middle of it, the FDA seized thousands of counterfeit Ozempic units from the legitimate supply chain and told the public not to use the fakes, flagging a specific lot and warning that even the needles were counterfeit and of unknown sterility. A national safety alert was live. And prosecutors say this alleged pipeline kept shipping for months anyway, into the spring of 2024. The charges did not come until September 2026. A seizure and a countrywide warning did not close the pipe, and an indictment nearly two years later is what arrived in its place.

Here is where I had to stop and sit with the chemistry, because it’s the reason “fake” undersells the danger. Real semaglutide is a GLP-1 receptor agonist, and the thing I keep coming back to is how conditional it is: it only tells your pancreas to pour out insulin when your blood sugar is already high. It works glucose-dependently. High sugar, it nudges. Normal sugar, it mostly leaves you alone. That built-in brake is why it doesn’t send an ordinary patient into a crash.

Now think about what a counterfeit throws away. The WHO’s alert on falsified Ozempic warned that the fakes, none of them made by Novo Nordisk, could carry unknown or substituted ingredients and be life-threatening. European regulators went further on the injuries, reporting hypoglycemia and seizures among people who used the counterfeits, some of them hospitalized. Put those two things side by side. A substituted ingredient plus blood sugar crashing to the floor is the fingerprint of insulin, a hormone with no glucose-dependent brake at all. Insulin drops your glucose whether it’s high, normal, or already low, and it does it fast. So a person who thinks they’re injecting a gentle, glucose-sensing nudge could be shoving their blood sugar off a cliff, with no idea. In the U.S., the FDA was investigating hospitalizations tied to suspected fakes by late 2023. And the counterfeit needles are their own problem: non-sterile hardware going under the skin, week after week, is a quiet infection risk stacked on top.

So why does any of this reach the legitimate supply at all? Because demand ran miles ahead of supply. Ozempic and Wegovy sat in shortage through the exact window the indictment describes, squeezed by a wave of diabetes and weight-loss prescriptions the manufacturer couldn’t fill. Scarcity plus a high price plus everybody wanting it is a purpose-built market for counterfeiters, and they know it. The fakes came in, as the indictment puts it, at heavily discounted prices, and a discount is engineered to hook the people who’ve already been priced out. The FDA declared the shortage resolved in February 2025, but the fakes didn’t clear out with it. That April, the agency flagged yet another counterfeit lot in the supply chain.

An indictment is an allegation, not a conviction. It’s also not proof the supply is clean now. Since 2023 the FDA has announced 3 separate seizures of counterfeit Ozempic from the legitimate chain, customs has intercepted unapproved semaglutide and tirzepatide, and that April 2025 lot shows the hole keeps reopening. Acting FDA Commissioner Kyle Diamantas called counterfeits in the drug supply a direct threat to public health and patient safety, and on that he’s right: interdicting foreign fakes at the border and prosecuting the smugglers is the job, and it’s worth doing loudly. But two men charged in Florida does not seal a gap that keeps splitting back open. It confirms the gap exists, and that the reassurance from the top has been outrunning the enforcement on the ground.

What actually changes for you is smaller and more practical than any press release makes it sound. A charge in a Florida courtroom does not check the pen in your fridge. If you’re on semaglutide, the boring defenses are the ones that hold. Fill it at a licensed pharmacy you trust. Read the lot number and match it against the FDA’s posted counterfeit lots. Treat any pen that showed up cheap through an online seller or a side channel as guilty until proven otherwise. If the packaging looks a hair off, if the pen feels wrong, if the needle isn’t what you’re used to, that instinct is worth more than the savings.

Me, I keep coming back to that glucose-dependent brake, because it’s the entire reason this drug is as safe as it is, and it’s the exact thing a counterfeit throws out. I would never buy a semaglutide pen off a marketplace listing or a too-good price. If I were relying on this medication, I’d rather wait out a backorder at a real pharmacy than gamble on a pen that might be insulin wearing an Ozempic label. A dud just fails to help you. This one can do the opposite, faster than you’d have time to notice.

Sources

1. FDA: Investigation Leads to Charges Against Two Indian Nationals (September 29, 2026)
2. FDA: Warns Consumers Not to Use Counterfeit Ozempic Found in U.S. Drug Supply Chain (December 2023)
3. FDA Roundup: December 22, 2023, seizure of thousands of counterfeit units
4. WHO: Medical Product Alert N°2/2024, Falsified Ozempic (semaglutide)
5. Euronews: Global health authorities warn on falsified Ozempic injection pens
6. CBS News: FDA investigating reports of hospitalizations after fake Ozempic
7. Partnership for Safe Medicines: GLP-1 safety risks update (May 2026)
8. NBC News: FDA warns of fake Ozempic in U.S. supply chain